[Resistant mechanism and treatment strategy of tyrosine kinase inhibitors]

Zhongguo Fei Ai Za Zhi. 2011 Oct;14(10):806-10. doi: 10.3779/j.issn.1009-3419.2011.10.07.

[Article in Chinese]

Authors

Jianbing Qiao¹, Wenping Chen

Affiliation

¹ Department of Medical Respiration, Nanjing Chest Hospital, China. baqiao0431@126.com

PMID: 22008111
PMCID: PMC5999947
DOI: 10.3779/j.issn.1009-3419.2011.10.07

No abstract available

Publication types

Review

MeSH terms

Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / metabolism
Drug Resistance, Neoplasm / drug effects*
Drug Resistance, Neoplasm / genetics
ErbB Receptors / antagonists & inhibitors*
ErbB Receptors / genetics
ErbB Receptors / metabolism
Gefitinib
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / metabolism
Protein Kinase Inhibitors / therapeutic use*
Quinazolines / therapeutic use
Treatment Outcome

Substances

Protein Kinase Inhibitors
Quinazolines
ErbB Receptors
Gefitinib